Organization of medical care and drug provision for patients with chronic hepatitis C in Moscow (in Russian only)

E.A. Nurmukhametova

Infectious Clinical Hospital №1 of the Moscow Department of Health, Moscow, Russia

N.P. Blokhina

Infectious Clinical Hospital №1 of the Moscow Department of Health, Moscow, Russia

S.V. Smetanina

Infectious Clinical Hospital №1 of the Moscow Department of Health, Moscow, Russia

Organization of medical care and drug provision for patients with chronic hepatitis C in Moscow (in Russian only)

Authors:

E.A. Nurmukhametova, N.P. Blokhina, S.V. Smetanina

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2019;8(1): 84‑92

DOI: 10.17116/dokgastro2019801184

Downloaded: 63

To cite this article:

Nurmukhametova EA, Blokhina NP, Smetanina SV. Organization of medical care and drug provision for patients with chronic hepatitis C in Moscow (in Russian only). Russian Journal of Evidence-Based Gastroenterology. 2019;8(1):84‑92. (In Russ., In Engl.)
https://doi.org/10.17116/dokgastro2019801184

Доказательная гастроэнтерология: pro et contra

Актуальные вопросы педиатрической практики

Использование инфографики авторами научных работ

Close metadata

The problem of chronic viral hepatitis C is among the most actual global health problems. The article is devoted to organization of medical care and drug provision for patients with chronic hepatitis C in Moscow. Considering high relevance of chronic viral hepatitis C for city healthcare, Moscow Department of Health initiated drug provision program for citizens with chronic viral hepatitis C. Practical implementation of the program began in 2016 as a part of the Moscow State Program «Development of Moscow Health Care in 2012—2020». The aim of the work was to analyze the results of implementation of drug provision program for patients with chronic hepatitis C in Moscow. Material and methods. The work was carried out by the specialists of the Center for the Treatment of Chronic Viral Hepatitis that is a structural unit of the Infectious Clinical Hospital №1. Current antiviral combinations and modes of therapy were administered: genotype 1 — Viekira Pak (n=642), Viekira Pak + ribavirin (n=259), daclatasvir + asunaprevir (n=745) and triple therapy PEG — IFN + ribavirin + simeprevir (n=896); genotypes 2 and 3 — standard combination of PEG-IFN + ribavirin. Overall number of patients provided with antiviral medicines in 2016—2018 was 6735. Results. The effectiveness of treatment (persistent response in 12 weeks after the end of the course) ranged from 88.6 to 97%. These results correspond to those of the world’s leading clinics and are accompanied by decrease of the incidence of chronic viral hepatitis C in Moscow.

Keywords:

chronic hepatitis C

treatment of hepatitis C in Moscow

antiviral treatment of hepatitis C

Authors:

E.A. Nurmukhametova

Infectious Clinical Hospital №1 of the Moscow Department of Health, Moscow, Russia

N.P. Blokhina

Infectious Clinical Hospital №1 of the Moscow Department of Health, Moscow, Russia

S.V. Smetanina

Infectious Clinical Hospital №1 of the Moscow Department of Health, Moscow, Russia

List of references:

Nikitin IG, Popovich LD, Potapchik EG. The economic burden of chronic hepatitis C in Russia. Epidemiologia I infectionnye bolezni. Actualnye voprosy. 2015;6:9-13. (In Russ.)
Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of Disease Severity on Healthcare Costs in Patients With Chronic Hepatitis C (CHC) Virus Infection. Hepatology. 2012 Nov;56(5):1651-1660. Epub 2012 Oct 9. https://doi.org/10.1002/hep.25842
Shestakova IV, Popovich LD, Potapchik EG, Blokhina NP. Possible socioeconomic effect of the introduction of innovative treatment technology for chronic hepatitis C in Russia. Epidemiologia I infectionnye bolezni. Actualnye voprosy. 2016;2:15-24. (In Russ.)
Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr; 49(4):1335-1374. https://doi.org/10.1002/hep.22759
Burnevich EZ, Shanitsina SE. Principles of interferon-based antiviral treatment for chronic hepatitis C. Clinicheskaya farmacologia i terapiya. 2016;25(1). (In Russ.)
Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680. https://doi.org/10.1056/NEJM200012073432302
Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. N Engl J Med. 2000 Dec 7;343(23):1673-1680. https://doi.org/10.1111/j.1365-2893.2012.01617.x
Esteban R, Buti M. Triple therapy with boceprevir or telaprevir for prior HCV non-responders. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):445-453. https://doi.org/10.1016/j.bpg.2012.09.001
Waldenström J, Färkkilä M, Rembeck K, et al. Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scand J Gastroenterol. 2016 Mar 3;51(3):337-343. https://doi.org/10.3109/00365521.2015.1087588
Miyake Y, Iwasaki Y, Yamamoto K. Metaanalysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer. 2010 Aug 15;127(4):989-996. https://doi.org/10.1002/ijc.25090
Torres H.A. et.al. AASLD, the liver mitting, ads.764.
Soriano V, Young B, Reau N. Report of the International Conference on Viral Hepatitis-2017. AIDS Rev. 2018 Jan-Mar;20(1):58-70.
Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. National Examination of HCV likage to care in the United States (2013—2016) based on large real-world dataset. Adv Ther. 2018 Jul;35(7):1087-1102. Epub 2018 Jun 9. https://doi.org/10.1007/s12325-018-0721-1
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR.PEARL-III Study; PEARL-IV Study. ABT-450/r—Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983-1992. Epub 2014 May 4. https://doi.org/10.1056/NEJMoa1402338
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; on behalf of the HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 1;384(9954):1597-1605. Epub 2014 Jul 28. https://doi.org/10.1016/S0140-6736(14)61059-X
Blokhina NP, Nurmuhametova EA, Rusanova MG, Gagarina IV, Mar’yamova ES, Kuznetsova NA, Mar’janovskaya TV, Lopatina TV, Kuzina OV, Alekseeva IN, Devyatkin AV, Linkova YuN, Morozova MA. The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice. Journal Infectology. 2016;8(2):48-55. (In Russ.)
Stefan Zeuzem, Jacobson IM, Tolga Baykal, Rui T. Marinho, Fred Poordad, Marc Bourlière, Mark S. Sulkowski, Heiner Wedemeyer, Edward Tam, Paul Desmond, Donald M. Jensen, Adrian M. Di Bisceglie, Peter Varunok, Tarek Hassanein, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, and Barry Bernstein. Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 370;17. https://doi.org/10.1056/NEJMoa1401561
Thomas Berg, Uwe Naumann, Albrecht Stoehr, Christoph Sick, Gerlinde Teuber, Willibold Schiffelholz, Stefan Mauss, Jan Hettinger, Henning Kleine, Andreas Pangerl, Claus Niederau. First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: data from the German hepatitis C-registry. Reported by Jules Levin EASL-53rd Annual Meeting of the European Association for the Study of the Liver Paris, France 13 April 2018.
Tarik Asselah, Stanislas Pol, Christophe Hezode, Veronique Loustaud-Ratti, Vincent Leroy, Si Nafa Si Ahmed, Violaine Ozenne, Jean-Pierre Bronowicki, Dominique Larrey, Albert Tran, Laurent Alric, Eric Nguyen-Khac, Michael Robertson, George J. Hanna, Deborah Brown, Ernest Asante-Appiah, Steve Ludmerer, Feng-Hsiu Su, Peggy Hwang, Stephanie Klopfer, Frank Dutko, Amir Guidoum, Karin Hagen, Barbara Haber, Rohit Talwani. Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants. Reported by Jules Levin EASL 2018 — International Liver Congress Paris, France 12 April 2018.
Pol S, Corouge M, Vallet-Pichard A. Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepatic Medicine: Evidence and Research. 2016:8:21-26. https://doi.org/10.2147/HMER.S62014

Close metadata